- Aryl carboxylic acid reduction and further reactions with GABA and glucose promoted by whole cells of Xylaria arbuscula
-
Xylaria arbuscula was collected from a Cypress tree, Cupressus lusitanica. The whole cells of this endophytic fungus were used in screening for microbial bioreduction of aryl acids. Different p-substituted benzoic acids were evaluated. However, only p-bromobenzoic acid, p-chlorobenzoic acid and p-nitrobenzoic acid were converted to their corresponding alcohols. Aryl acid metabolism of X. arbuscula included GABA incorporation and glycosylation when the substrates were p-bromobenzoic and p-chlorobenzoic acids were also observed. The substrates p-hydroxybenzoic and p-aminobenzoic acids were not transformed. These results could suggest that electron-withdrawing groups at para orientation activate the substrate for reduction.
- Amaral, Luciana Da Silva,Rodrigues-Filho, Edson
-
-
- Acylhydrocarbylaminoalkanoic acids, compositions and uses
-
Compounds of the formula STR1 wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula STR2 R1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl; R2 is --H or lower aliphatic hydrocarbyl; R3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R4, alkylene; R4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R3, alkylene; or R2,R3 and R4, together with the carbon to which each is bound, are adamantyl; and n is 3, 4 or 5; and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are discussed.
- -
-
-